Login / Signup

Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis.

William E DamskyDurga ThakralNkiruka EmeagwaliAnjela GalanBrett King
Published in: The New England journal of medicine (2019)
There is evidence that Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling plays a role in the pathogenesis of sarcoidosis. We treated a patient with cutaneous sarcoidosis with the JAK inhibitor tofacitinib; the patient had not previously had a response to medications and had not received systemic glucocorticoids. This treatment resulted in clinical and histologic remission of her skin disease. Sequencing of RNA and immunohistochemical examination of skin-lesion samples obtained from the patient before and during therapy and immunohistochemical testing of lesion samples obtained from other patients with cutaneous sarcoidosis support a role for JAK-STAT signaling in cutaneous sarcoidosis. (Funded by the Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research and others.).
Keyphrases
  • case report
  • rheumatoid arthritis
  • ulcerative colitis
  • single cell
  • cell proliferation
  • immune response
  • disease activity
  • nuclear factor
  • systemic lupus erythematosus
  • newly diagnosed
  • high throughput sequencing